Fly News Breaks for September 13, 2017
Sep 13, 2017 | 08:07 EDT
Cantor Fitzgerald analyst Mara Goldstein in a research note yesterday afternoon attributed the selloff in shares of NewLink Genetics to the market digesting the updated indoximod dataset. The stock traded off on concerns that non-evaluable patients were not included, but this was known based on the press release on September 7, Goldstein told investors. The data represented the 51 non-ocular melanoma patients reported on at AACR 2017, and the analyst expects the final data for all patients at some point. She still likes indoximod and kept an Overweight rating on NewLink with a $26 price target.
News For NLNK From the Last 2 Days
There are no results for your query NLNK